3.2 Compliance
The compliance rate was 100% for both the SHR2554 administration phase and the rifampin administration phase (all 18 subjects received all planned doses of SHR2554 or rifampin). In the coadministration phase, the compliance rate was 94.4%, and 1 subject withdrew from the study due to AEs.